Therefore, the mechanism of key CMM combinations in treating mastitis may be that they inhibit the activity of NF-κB signaling pathway, block the NF-κB-mediated expression of various cytokines, and thus exert therapeutic effects on mastitis. The gene discussed is NFKB1; the disease is mastitis.